Drugs in Dev. Oncology
Phase II
Italy 
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fidia FDA Orphan Drug Designation for ONCOFID®-P for Malignant Mesothelioma
Details : ONCOFID®-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
Product Name : Oncofid-P
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cusatuzumab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Termination
Details : The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.
Product Name : JNJ-74494550
Product Type : Antibody
Upfront Cash : Undisclosed
July 06, 2021
Lead Product(s) : Cusatuzumab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Termination
Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer
Details : Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally-advanced, not metastatic nonmelanoma skin cancer. Patients enrolled in the study will be treated with intralesional injection...
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
June 26, 2020
Reset All
